Lobular - but not periovular - inhibition of collagen deposition in the liver of S. Mansoni infected mice using interferon-γ

Journal of Hepatology

Volumn 26, Issue 4, 1997, Pages 894-903

  Lortat Jacob, Hugues ^a   Baltzer, Frederic ^a   Desmoulière, Alexis ^a   Peyrol, Simone ^a   Grimaud, Jean Alexis ^a  

^a CNRS   (France)

Author keywords

fibrosis; heparan sulfate; interferon; liver

Indexed keywords

COLLAGEN; GAMMA INTERFERON; HEPARAN SULFATE;

ANIMAL EXPERIMENT; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; ELECTRON MICROSCOPY; FEMALE; HISTOLOGY; IMMUNOCYTOCHEMISTRY; INFLAMMATION; INTRAMUSCULAR DRUG ADMINISTRATION; LIVER DISEASE; LIVER FIBROSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SCHISTOSOMA MANSONI; SCHISTOSOMIASIS;

EID: 0031003583     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(97)80258-9     Document Type: Article

References (48)

1. Burt AD. Cellular and molecular aspects of hepatic fibrosis. J Pathol. 170:1993;105-114.
2. Friedman SL. The cellular basis of hepatic fibrosis. Mechanisms and treatment strategies. N Engl J Med. 328:1993;1828-1835.
3. Gressner AM. Liver fibrosis: perspectives in pathobiochemical research and clinical outlook. Eur J Clin Chem Clin Biochem. 29:1991;293-311.
4. Clément B, Grimaud JA, Campion JP, Deugnier Y, Guillouzo A. Cell types in collagen and fibronectin production in normal and fibrotic human liver. Hepatology. 6:1986;25-34.
5. Maher J, McGuire R. Extracellular matrix gene expression increases preferentially in rat lipocytes and sinusoidal endothelial cells during hepatic fibrosis in vivo. J Clin Invest. 86:1990;1641-1648.
6. Rockey DC, Boyles LK, Gabbiani G, Friedman SL. Rat hepatic lipocytes express smooth muscle action upon activation in vivo, and in culture. J Submicrosc Cytol Pathol. 24:1992;193-203.
7. Tuchweber B, Desmoulière A, Bochaton-Piallat ML, Rubbia-Brandt L, Gabbiani G. Proliferation and phenotypic modulation of portal fibroblasts in the early stages of cholestatic fibrosis in the rat. Lab Invest. 74:1996;1-14.
8. Cheever AW. Schistosomiasis infection versus disease, hypersensitivity versus immunity. Am J Pathol. 142:1993;699-705.
9. Boros DL. Immunopathology of Schistosoma mansoni infection. Microbiol Rev. 2:1989;250-269.
10. Chensue SW, Warmington KS, Lincoln PM, Kunkel SL. Cross-regulatory role of interferon-gamma (IFNγ), Il-4 and Il-10 in schistosome egg granuloma formation: in vivo regulation of Th activity and inflammation. Clin Exp Immunol. 98:1994;395-400.
11. Lukacs NW, Boros DL. Lymphokine regulation of granuloma formation in murine Schistosomiasis mansoni. Clin Immunol Immunopathol. 68:1993;57-63.
12. Wyler DJ. Why does liver fibrosis occur in schistosomiasis? Parasitol Today. 8:1992;277-279.
13. Andrade ZA, Cheever AW. Characterization of the murin model of schistosomal hepatic periportal fibrosis ('pipestem fibrosis'). Int J Exp Path. 74:1993;195-202.
14. Lukacs NW, Kundel SL, Strieter RM, Chensue SW. The role of chemokines in Schistosoma mansoni granuloma formation. Parasitol Today. 10:1994;322-324.
15. Grimaud JA. Cell-matrix interactions in schistosomal portal fibrosis: a dynamic event. Mem Inst Oswaldo Cruz. 82:1987;55-65.
16. Grimaud JA, Boros DL, Takiya C, Mathew RC, Emmonard H. Collagen isotypes, laminin and fibronectin in granulomas of the liver and intestine of S. mansoni infected mice. Am J Trop Med Hyg. 37:1987;332-345.
17. Kovacs EJ. Fibrogenic cytokines: the role of immune mediators in the development of scar tissue. Immunol Today. 12:1991;17-23.
18. Granstein RD, Rook A, Flotte TJ, Haas A, Gallo RL, Jaffe HS, Amento EP. A controlled trial of intralesional recombinant interferon-γ in the treatment of keloidal scarring. Arch Dermatol. 126:1990;1295-1302.
19. Pittet B, Rubbia-Brandt L, Desmoulière A, Sappino AP, Roggero P, Guerret S, Grimaud JA, Lacher R, Montandon D, Gabbiani G. Effect of γ-interferon on the clinical and biological evolution of hypertrophic scars and Dupuytren's disease: an open pilot study. Plast Reconstr Surg. 93:1994;1224-1235.
20. Freundlich B, Jimenez SA, Steen VD, Medsger TA, Szkolnicki M, Jaffe HS. Treatment of systemic sclerosis with recombinant interferon-γ. A phase I/II trial. Arthritis Rheum. 35:1992;1134-1142.
21. Van Loon APGM, Ozmen L, Fountoulakis M, Kania M, Haiker M, Garotta G. High-affinity receptor for interferon-gamma (IFNγ), a ubiquitous protein occurring in different molecular forms on human cells. J Leukocyte Biol. 49:1991;462-476.
22. Lortat-Jacob H, Kleinmann HK, Grimaud JA. High-affinity binding of interferon-γ to a basement membrane complex (matrigel). J Clin Invest. 87:1991;878-883.
23. Lortat-Jacob H, Grimaud JA. Binding of interferon-gamma to heparan sulfate is restricted to the heparin-like domains and involves carboxylic - but not N-sulfated - groups. Biochim Biophys Acta. 1117:1992;126-130.
24. Lortat-Jacob H, Brisson C, Guerret S, Morel G. Non-recetor-mediated tissular localization of human interferon-γ: role of heparan sulfate/heparin-like molecules. Cytokine. 8:1996;557-566.
25. Silva LCF, Borojevic R, Mourao PA. Proteoglycans synthesized by the hepatic granulomas isolated from schistosome-infected mice and by the granuloma-derived connective tissue cell lines. Biochim Biophys Acta. 1139:1992;96-104.
26. Praillet C, Lortat-Jacob H, Baltzer F, Grimaud JA. Distribution of hepatic glycosaminoglycans during acute schistosomiasis: modulation by IFN-γ treatment. Cell Mol Biol. 42:1996;169-177.
27. Lortat-Jacob H, Baltzer F, Grimaud JA. Heparin decreases the blood clearance of interferon-γ and increases its activity by limiting the processing of its carboxyl-terminal sequence. J Biol Chem. 271:1996;16139-16143.
28. Andrade ZA, Grimaud JA. Evolution of the schistosomal hepatic lesions in mice after curative chemotherapy. Am J Pathol. 124:1986;59-65.
29. Cantell K, Schellekens H, Pyhälä L, Hirvonen S, Van Der Meide PH, De Reus A. Pharmacokinetics studies with human and rat interferon-γ in different species. J Interferon Res. 6:1986;671-675.
30. Woessner JF. The determination of hydroxyproline in tissue and protein samples containing small proportions of this imino acid. Arch Biochem Biophys. 93:1961;440-447.
31. Pellegrino J, Brener Z. Method for isolating schistosome granulomas from mouse liver. J Parasitol. 42:1976;564-4.
32. Esterre P, Guerret S, Grimaud JA. Application of image analysis to the study of skin granulomas. Anal Cell Pathol. 8:1995;191-201.
33. Skalli O, Ropraz P, Trzeciak A, Benzonana G, Gillessen D, Gabbiani G. A monoclonal antibody against α-smooth muscle actin: a new probe for smooth muscle differentiation. J Cell Biol. 103:1986;2787-2796.
34. El Meneza S, Olds GR, Kresina TF, Mahmoud AA. Dynamics of hepatic connective tissue matrix constituents during Schistosoma mansoni infection. Hepatology. 9:1989;50-56.
35. Rockey DC, Maher JJ, Jarnagin WR, Gabbiani G, Friedman SL. Inhibition of rat hepatic lipocyte activation in culture by interferon-γ Hepatology. 16:1992;776-784.
36. Mallat A, Preaux AM, Blazejewski S, Rosenbaum J, Dhumeaux D, Mavier P. Interferon alfa and gamma inhibit proliferation and collagen synthesis of human Ito cells in culture. Hepatology. 21:1995;1003-1010.
37. Clément B, Loréal O, Levavaseur F, Guillouzo A. New challenges in hepatic fibrosis. J Hepatol. 18:1993;1-4.
38. Rockey DC, Chung JJ. Interferon-γ inhibits lipocyte activation and extracellular matrix mRNA expression during experimental liver injury: implication for treatment of hepatic fibrosis. J Invest Med. 42:1994;660-670.
39. Czaja MJ, Weiner FR, Takahashi S, Giambrone MA, Van Der Meide PH, Schellekens H, Biempica L, Zern MA. γ-interferon treatment inhibits collagen deposition in murine schistosomiasis. Hepatology. 10:1989;795-800.
40. Svegliati Baroni G, Curto P, Mancini R, Benedetti A, Jezequel AM, Orlandi F. Interferon-gamma treatment reduces lipocyte activation and collagen deposition in liver fibrosis. Gastroenterology. 106:1994;A992.
41. Okada T, Sugie I, Aisaka K. Effect of γ-interferon on collagen ad histamine content in bleomycin-induced lung fibrosis in rats. Lymphokin Cytokin Res. 12:1993;87-91.
42. Emonard H, Peyrol S, Grimaud JA. Tissue hyperfibrils are degraded forms of collagen fibrils. An ultrastructural study employing enzymatic treatments. J Submicrosc Cytol Pathol. 23:1991;427-430.
43. Matsuoka M, Pham NT, Tsukomoto H. Differential effects of interleukin-1 alpha, tumor necrosis factor alpha and transforming growth factor beta 1 on cell proliferation and collagen formation by cultured fat-storing cells. Liver. 9:1989;71-78.
44. Wyler DJ, Ehrlich HP, Postlethwaite AE, Raghow R, Murphy M. Fibroblast stimulation in schistosomiasis. Egg granulomas secrete factors that stimulate collagen and fibronectin synthesis. J Immunol. 138:1987;1581-1586.
45. Lortat-Jacob H, Turnbull JE, Grimaud JA. Molecular organization of the interferon-γ binding domain in heparan sulphate. Biochem J. 310:1995;497-505.
46. Lortat-Jacob H, Grimaud JA. Interferon-γ binds to heparan sulfate by a cluster of amino acids located in the C-terminal part of the molecule. FEBS Lett. 280:1991;152-154.
47. Stow JL, Kjéllen L, Unger E, Höök M, Farquhar G. Heparan sulfate proteoglycans are concentrated on the sinusoidal plasmalemmal domain and intracellular organelles of hepatocytes. J Cell Biol. 100:1985;975-980.
48. Roskams T, Moshage H, De Vos R, Guido D, Yap D, Desmet V. Heparan sulfate proteoglycan expression in normal human liver. Hepatology. 21:1995;950-958.